Joseph Papa thinks he’s the man to turn Valeant around.
The reason he is so confident: the company’s drug pipeline.
The new CEO of Valeant Pharmaceutical said in his first interview since taking the role that the company has great brands.
“But you know the biggest surprise and the reason that really got me? I looked at their pipeline,” he told CNBC Mad Money’s Jim Cramer. “Because to me, that’s going to predict how is a company successful in the future. Are they going to grow organically or not?”
Papa said the company has 10 new drugs that they expect to launch in the next year and a half.
Papa’s compensation, if he manages to turn things around, is $65 million. When pressed by Cramer, he said he’s not in it for the money.
“This is an industry that does more good for people than any other industry at least as far as I’m concerned,” he said.
“I’m a pharmacist by my training. To me, this was all about if I could play a small role in improving Valeant, and if that has a beneficial impact on the entire pharmaceutical industry, I think I will have done something that’s important.”
Papa’s only a week into his new gig, and he said his first priority is to “re-recruit” Valeant employees.
“Get their engagement back. That’s an important message. They have had a tough nine months. There’s no doubt about that,” he said.
He was also asked if the company would be rolling back prices on drugs. Papa said he doesn’t yet know if that will happen.
“I don’t know the action yet, but we’re clearly going to look at patient access, and make sure that if people want our drugs, they get access to our drugs,” he said.
NOW WATCH: Humans are defying the law of evolution
NOW WATCH: Briefing videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.